You are viewing a single comment's thread.

view the rest of the comments →

0
1

[–] Thereunto [S] 0 points 1 point (+1|-0) ago 

CNN's article references a few items, but the main component is the Lancet article. Here's what my superficial research revealed:

Lancet article:

"The association of decreased survival with hydroxychloroquine or chloroquine treatment regimens should be interpreted cautiously. Due to the observational study design, we cannot exclude the possibility of unmeasured confounding factors, although we have reassuringly noted consistency between the primary analysis and the propensity score matched analyses. Nevertheless, a cause-and-effect relationship between drug therapy and survival should not be inferred."

Study uses WHO guidelines for diagnosis: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf

The WHO guideline states "The most common diagnosis in severe COVID-19 patients is severe pneumonia." (Pneumonia is treatable by Azithromycin)

WHO guideline: "Older patients and those with comorbidities, such as cardiovascular disease and diabetes mellitus, have increased risk of severe disease and mortality."

Note: the administered dosages / dose scheme for treatment (CQ/HCQ + macrolide) is not in the article (as of May 23). Nor does it appear in the supplementary information file.

Funding from:

Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, Baim Institute for Clinical Research, NupulseCV, FineHeart, Leviticus, Roivant, and Triple Gene

(company - business)

(url to demonstrate)

Abbott - vaccines & implant medical devices

https://www.nzherald.co.nz/business/news/article.cfm?c_id=3&objectid=12321112

https://www.cardiovascular.abbott/us/en/patients/living-with-your-device/heart-failure/pulmonary-pressure-artery-monitoring/cardiomems-hf-system.html

Meditronic - ventilators

https://www.marketwatch.com/press-release/medtronic-provides-update-on-covid-19-pandemic-response-and-impact-2020-04-22

Janssen Pharmaceuticals Inc - vaccines

https://web.archive.org/web/20191105161649/https://www.marketwatch.com/press-release/investigational-ebola-vaccine-from-janssen-and-bavarian-nordic-to-support-outbreak-response-in-democratic-republic-of-the-congo-2019-10-31

Mesoblast (previously Teva) - produces mesenchymal stem cells (can be IV administered). Targetted injections known to cause bleeding and tissue damage in rodents. The technology has trouble getting passed the heart on the first IV travel. Currently seeking FDA approval for proprietary covid-19 drug Ryoncil. Current product remestemcel-L for ARDS caused by Covid19. Company previously critized for fudging results to push products.

https://www.marketwatch.com/press-release/fda-clears-investigational-new-drug-application-for-mesoblast-to-use-remestemcel-l-in-patients-with-acute-respiratory-distress-syndrome-caused-by-covid-19-2020-04-06-6184027

https://en.wikipedia.org/wiki/Mesoblast

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190292/

https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus

Portola Pharmaceuticals - produces coagulant (bleeding remedy) AndexXa -- currently merging with Alexion - produces Soliris, proprietary Covid19 drug requiring vaccination before use

https://www.globaldata.com/alexion-to-start-soliris-in-covid-19-phase-ii-trial-in-next-few-days-says-globaldata/

https://www.drugs.com/soliris.html

Bayer - vaccines

https://www.bayer.com/en/coronavirus-covid-19-update.aspx

Baim Institute for Clinical Research - nonprofit. Clinical trial design. Sponsors and contributes to vaccine research

https://www.baiminstitute.org/index.php/services/

https://www.sciencedirect.com/science/article/pii/S0002870318301571

NupulseCV - implant medical devices (heart)

https://www.nupulsecv.com/technology/

FineHeart - implant medical devices (heart)

http://fineheart.fr/icoms-new-technology/

Leviticus Cardio LTD - implant medical devices (heart)

https://www.bloomberg.com/profile/company/1259186D:IT

Roivant - drug BREATHE (for ARDS), drug gimsilumab (immunosuppressant) for Covid19

https://roivant.com/roivant-doses-first-patient-in-pivotal-breathe-clinical-trial-evaluating-gimsilumab-in-covid-19-patients.html

Triple Gene - stem cell products. Developing INXN4001 for heart regeneration

https://clinicaltrials.gov/ct2/show/NCT03409627

0
0

[–] divine_human ago 

Good stuff, thanks for the research and compilation. A keeper...